Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Hepion Pharmaceuticals, Inc. | c771-20201231ex312f19580.htm |
| 10-K - 10-K - Hepion Pharmaceuticals, Inc. | c771-20201231x10k.htm |
| EX-32.2 - EX-32.2 - Hepion Pharmaceuticals, Inc. | c771-20201231ex322a82adf.htm |
| EX-32.1 - EX-32.1 - Hepion Pharmaceuticals, Inc. | c771-20201231ex32120a08c.htm |
| EX-31.1 - EX-31.1 - Hepion Pharmaceuticals, Inc. | c771-20201231ex3110b4727.htm |
| EX-21.1 - EX-21.1 - Hepion Pharmaceuticals, Inc. | c771-20201231ex211762fef.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
Hepion Pharmaceuticals, Inc.
Edison, New Jersey 08837
We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-229534) and Form S-8 (Nos. 333-252188, 333-203867, 333-215662 and 333-234728) of Hepion Pharmaceuticals, Inc. of our report dated March 31, 2021, relating to the consolidated financial statements, which appears in this Annual Report on Form 10-K.
/s/ BDO USA, LLP
Woodbridge, New Jersey
March 31, 2021